Skip to main content

Table 2 Laboratory parameters of SLE patients with/without HM at the baseline

From: Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis—a case-control study

Parameters

Group A

(n=15)

Group B

(n=57)

P value

Hematological abnormality (n, %)

13 (86.7)

39 (68.4)

0.280

WBC (×109), M (Q1-Q3)

3.40 (1.80–5.68)

3.90 (2.85–6.25)

0.072

RBC (×1012, mean ± SD)

3.08±0.88

3.59±0.64

0.016*

Hb (g/L, mean ± SD)

89.97±23.18

103.43±20.41

0.031*

Platelet (×109, mean ± SD)

118.80±64.68

160.54±82.66

0.074

Urine protein positivity (n, %)

5 (33.3)

27 (47.4)

0.330

24hTP (g), M (Q1–Q3)a

0.49 (0.29–1.13)

1.40 (0.36–4.92)

0.156

Scr (umol/L), M (Q1–Q3)

62.00 (47.50–73.50)

55.00 (47.50–73.50)

0.856

GFR (ml/min/1.73m2), M (Q1–Q3)

85.57 (77.04–109.31)

108.76 (91.70–121.71)

0.099

TP (g/L, mean ± SD)

66.88±11.74

64.72±13.16

0.567

Albumin (g/L, mean ± SD)

29.70±6.69

31.72±7.58

0.351

Globin (g/L, mean ± SD)

37.18±13.39

33.33±9.64

0.310

Lupus nephritis (n, %)

5 (33.3)

28 (49.1)

0.275

TC (mmol/L), M (Q1–Q3)

3.05 (2.54–3.45)

3.91 (3.09–4.56)

0.030*

TG (mmol/L), M (Q1–Q3)

1.33 (0.75–2.02)

1.64 (1.20–2.37)

0.157

HDL (U/L), M (Q1–Q3)

0.61 (0.42–0.69)

0.96 (0.77–1.16)

0.003*

LDL (U/L), M (Q1–Q3)

1.74 (1.11–2.34)

2.39 (1.67–2.95)

0.058

ALT (U/L), M (Q1–Q3)

24.00 (10.00–35.00)

23.00 (13.00–49.00)

0.682

AST (U/L), M (Q1–Q3)

29.00 (17.00–58.00)

28.00 (18.00–56.50)

0.950

LDH(U/L), M (Q1–Q3)

262.00 (197.00–453.00)

273.00 (206.00–614.00)

0.767

EBV-IgM+ (n, %)

0 (0/7, 0)

2 (2/20, 10.0)

0.975

EBV-IgG+ (n, %)

7 (7/7, 100)

20 (20/20, 100)

-

C3 (g/L, mean ± SD)

0.78±0.35

0.67±0.36

0.314

C4 (g/L, mean ± SD)

0.16±0.12

0.13±0.08

0.401

ESR (mm/h), M (Q1–Q3)

48.00 (34.50–100.25)

41.50 (19.75–74.00)

0.533

CRP (mg/L), M (Q1–Q3)

16.31 (2.82–34.71)

3.88 (1.50–7.17)

0.018*

Ferritin (ng/ml), M (Q1–Q3) b

692.45(475.20–1248.28)

188.85 (71.92–369.53)

0.007*

SLEDAI-2K, M (Q1–Q3)

9.00 (4.00–14.00)

12.00 (8.00–18.00)

0.184

ANA (n, %)

15 (100)

57 (100)

-

Anti-dsDNA antibody (n, %)

4 (26.7)

38 (66.7)

0.005*

Anti-Smith antibody (n, %)

5 (5/11, 45.5)

19 (19/50, 38.0)

0.907

Anti-Rib P (n, %)

4 (4/14, 28.6)

26 (26/54, 48.1)

0.189

Anti-Nuc (n, %)

5 (5/12, 41.7)

31 (31/55, 56.4)

0.355

Anti-His (n, %)

3 (3/13, 23.1)

25 (25/54, 46.3)

0.128

Anti-SSA/Ro52 (n, %)

9 (9/13, 69.2)

24 (24/52, 46.2)

0.137

Anti-SSA/Ro60 (n, %)

8 (8/12, 66.7)

26 (26/49, 53.1)

0.395

Anti-SSB (n, %)

4 (4/12, 33.3)

9 (9/53, 17.0)

0.379

ACA (n, %)

2 (2/8, 25.0)

2 (2/49, 4.1)

0.161

APL (n, %)

4 (4/7, 57.1)

15 (15/27, 55.6)

1.000

  1. * Statistical significance (P<0.05)
  2. Group A: SLE patients with hematological malignancies; Group B: SLE patients without hematological malignancies
  3. Hematological abnormality: Patients present with leukopenia (WBC<3.5×109), anemia (Hb<120g/L for male or Hb<110g/L for female), or thrombocytopenia (platelet<100×109)
  4. Urine protein positivity: 24-h total urinary protein >0.15g or spot urine protein/creatinine ratio>200mg/g or positive results in qualitative test of urinary protein
  5. Lupus nephritis: 24-h total urinary protein ≥ 0.5g or the confirmation of renal biopsy
  6. a The data of Group A (7 patients) and Group B (29 patients)
  7. b The data of Group A (6 patients) and Group B (20 patients)
  8. Abbreviations: SLE systemic lupus erythematosus, HM hematological malignancies, WBC white blood cell, RBC red blood cell, Hb hemoglobin, 24hTP 24-h total urinary protein, Scr serum creatinine, GFR glomerular filtration rate, TP total protein, TC total cholesterol, TG triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein, ALT alanine transaminase, AST aspartate transaminase, LDH lactic dehydrogenase, EBV Epstein-Barr virus, CMV cytomegalovirus, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SLEDAI-2K systemic lupus erythematosus disease activity index-2000, ANA anti-nuclear antibody, Anti-Rib P anti-ribosomal P-protein antibody, Anti-Nuc anti-nucleosome antibody, Anti-His anti-histone antibody, ACA anti-centromere antibody, APL anti-phospholipid antibody